Evidence map›Paper›PMID 32191726›Full record

ArticlePloS one2020

Podocyte-specific deletion of tubular sclerosis complex 2 promotes focal segmental glomerulosclerosis and progressive renal failure.

Wakiko Iwata, Hiroyuki Unoki-Kubota, Hideki Kato, Akira Shimizu, Michihiro Matsumoto, Toshiyuki Imasawa, Arisa Igarashi, Kenji Matsumoto, Tetsuo Noda, Yasuo Terauchi and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Podocyte cell-specificPhysiological genomics · 2024
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Wakiko IwataDepartment of Diabetic Complications, Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Hiroyuki Unoki-KubotaDepartment of Diabetic Complications, Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.ORCID 0000-0003-4827-8805
Hideki KatoDivision of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Akira ShimizuDepartment of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.
Michihiro MatsumotoDepartment of Molecular Metabolic Regulation, Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Toshiyuki ImasawaKidney Center, National Hospital Organization Chiba-Higashi National Hospital, Chiba, Japan.
Arisa IgarashiDepartment of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.
Kenji MatsumotoDepartment of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.
Tetsuo NodaCancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan.
Yasuo TerauchiDepartment of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
Masaomi NangakuDivision of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Masato KasugaNational Center for Global Health and Medicine, Tokyo, Japan.
Yasushi KaburagiDepartment of Diabetic Complications, Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
National Center for Global Health and Medicine · JPNational Center For Child Health and Development · JPThe University of Tokyo · JPJapanese Foundation For Cancer Research · JPNational Hospital Organization · JPNippon Medical School · JPYokohama City University · JP

Funding

Therapeutics Development Core (Core B)P30DK114857 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SCHNAPER, H WILLIAM · 2018 to 2022
$5.7M
NIDDK NIH HHS P30 DK114857
6 · The paper itself

Abstract

Obesity can initiate and accelerate the progression of kidney diseases. However, it remains unclear how obesity affects renal dysfunction. Here, we show that a newly generated podocyte-specific tubular sclerosis complex 2 (Tsc2) knockout mouse model (Tsc2Δpodocyte) develops proteinuria and dies due to end-stage renal dysfunction by 10 weeks of age. Tsc2Δpodocyte mice exhibit an increased glomerular size and focal segmental glomerulosclerosis, including podocyte foot process effacement, mesangial sclerosis and proteinaceous casts. Podocytes isolated from Tsc2Δpodocyte mice show nuclear factor, erythroid derived 2, like 2-mediated increased oxidative stress response on microarray analysis and their autophagic activity is lowered through the mammalian target of rapamycin (mTOR)-unc-51-like kinase 1 pathway. Rapamycin attenuated podocyte dysfunction and extends survival in Tsc2Δpodocyte mice. Additionally, mTOR complex 1 (mTORC1) activity is increased in podocytes of renal biopsy specimens obtained from obese patients with chronic kidney disease. Our work shows that mTORC1 hyperactivation in podocytes leads to severe renal dysfunction and that inhibition of mTORC1 activity in podocytes could be a key therapeutic target for obesity-related kidney diseases.

Indexed as

AutophagyAnimalsDisease Models, AnimalDisease ProgressionGlomerulosclerosis, Focal SegmentalHumansMaleMechanistic Target of Rapamycin Complex 1MiceMice, KnockoutMice, ObeseObesityPodocytesRenal Insufficiency, ChronicTuberous Sclerosis Complex 2 ProteinMechanistic Target of Rapamycin Complex 1Tsc2 protein, mouseTuberous Sclerosis Complex 2 Protein

Identifiers

PMID32191726
PMCPMC7082048
OpenAlexW3012535063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.